Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Neurol. 2011 Feb;69(2):408-13. doi: 10.1002/ana.22352.

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.

Author information

1
Department of Neurology, Clinical Neuroimmunology Laboratory, University Hospital Basel, Switzerland.

Abstract

T cells exit secondary lymphoid organs along a sphingosine1-phosphate (S1P) gradient and, accordingly, are reduced in blood upon fingolimod-mediated S1P-receptor (S1PR)-blockade. Serving as a model of adaptive immunity, we characterized cellular and humoral immune responses to influenza vaccine in fingolimod-treated patients with multiple sclerosis (MS) and in untreated healthy controls. Although the mode of action of fingolimod might predict reduced immunity, vaccine-triggered T cells accumulated normally in blood despite efficient S1PR-blockade. Concentrations of anti-influenza A/B immunoglobulin (Ig)M and IgG also increased similarly in both groups. These results indicate that fingolimod-treated individuals can mount vaccine-specific adaptive immune responses comparable to healthy controls.

PMID:
21387383
DOI:
10.1002/ana.22352
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center